Arcus Biosciences, Inc. 8-K

What Happened

• Arcus Biosciences, Inc. (RCUS) filed a Form 8‑K on May 5, 2026 to announce its financial results for the quarter ended March 31, 2026.
• The company furnished a press release dated May 5, 2026 as Exhibit 99.1 to the filing; that press release is incorporated by reference into the Form 8‑K.
• The filing was signed by Terry Rosen, Ph.D., Chief Executive Officer.

Key Details

• Filing date: May 5, 2026.
• Reporting period covered: three months ended March 31, 2026.
• Disclosure type: Item 2.02 (Results of Operations and Financial Condition); press release filed as Exhibit 99.1.
• Form signed by CEO Terry Rosen, Ph.D.

Why It Matters

• The 8‑K announces Arcus’s quarterly earnings information, which is a primary source for investors to assess recent revenue, expenses, cash position, and operational updates.
• The press release (Exhibit 99.1) contains the specific financial figures and commentary investors need; review that release and subsequent SEC filings (e.g., the quarterly 10‑Q) for details before making investment decisions.